Please use this identifier to cite or link to this item:
Title: Management of very high risk pregnancy with secondary anti-phospholipid syndrome and triple positivity to the anti-phospholipid antibodies.
Austin Authors: Rose, Hannah L;Ho, Wai Khoon 
Affiliation: Department of Haematology, Austin Health, Studley Road, Heidelberg, VIC, 3084, Australia
Issue Date: 1-Nov-2014
Publication information: Journal of Thrombosis and Thrombolysis; 38(4): 453-6
Abstract: There is a significantly increased risk of pregnancy complications in women with anti-phospholipid syndrome (APS). The risk is further heightened in those with previous arterial or venous thromboembolism and so-called 'triple positivity' for anti-phospholipid antibodies (i.e., when lupus anticoagulant, and anti-cardiolipin (aCL) and anti-β2 glycoprotein-I (anti-β2Gp-I) antibodies are all detected). Management of these cases is extremely difficult and little is available in the medical literature to guide therapy. This report describes the use of regular plasma exchanges (PEx) to bring about a successful pregnancy outcome in a woman with secondary APS and previous recurrent miscarriages. The patient was also anticoagulated with enoxaparin and administered aspirin, prednisolone, azathioprine and hydroxychloroquine. Through regular PEx and immunomodulation therapy, levels of aCL and anti-β2Gp-I antibodies were monitored and documented to fall as pregnancy progressed. Although the outcome in this case was successful, further experience is required before this regimen can be accepted as the standard of care for these patients at very high risk of pregnancy loss.
Gov't Doc #: 24777280
DOI: 10.1007/s11239-014-1080-7
Type: Journal Article
Appears in Collections:Journal articles

Files in This Item:
File SizeFormat 
24777280.pdf43.77 kBAdobe PDFView/Open
Show full item record

Page view(s)

checked on Nov 28, 2022


checked on Nov 28, 2022

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.